Compare REPL & RCAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REPL | RCAT |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Wholesale Distributors |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2018 | 2017 |
| Metric | REPL | RCAT |
|---|---|---|
| Price | $10.82 | $4.71 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $19.50 | $16.50 |
| AVG Volume (30 Days) | 1.8M | ★ 6.7M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $17,836,382.00 |
| Revenue This Year | N/A | $270.70 |
| Revenue Next Year | $497.81 | $45.18 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 79.95 |
| 52 Week Low | $1.50 | $4.41 |
| 52 Week High | $16.33 | $18.78 |
| Indicator | REPL | RCAT |
|---|---|---|
| Relative Strength Index (RSI) | 32.47 | 19.44 |
| Support Level | $6.81 | N/A |
| Resistance Level | $11.05 | $11.75 |
| Average True Range (ATR) | 0.71 | 0.27 |
| MACD | -0.20 | -0.09 |
| Stochastic Oscillator | 1.83 | 13.20 |
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
Red Cat Holdings Inc is a drone technology company integrating robotic hardware and software for military, government, and commercial operations. Its suite of solutions includes the Arachnid family of ISR and precision strike drones, which includes the Black Widow, a small unmanned ISR system; and WEB (Warfighter Electronic Bridge) GCS, designed to command and control an entire drone family of systems for military operations. Its other offerings include Edge 130 Blue drone systems, Trichon, a fixed-wing VTOL for extended endurance and range, and FANG FPV drones optimized for military operations with precision strike capabilities. The firm's Division includes Teal, FlightWave, and Blue Ops.